However, since G-CSF is unsafe and contraindicated in patients with sickle-cell disease, robust and rapid stem cell mobilization regimens lacking G-CSF are needed for autologous gene therapy for patients with sickle cell anemia, which may require >20 × 106 CD34+/kg. Here, CD34 is linked to sickle cell disease.